NotablePrimary endpoint(s) modifiedShow 7 more changesShow less
Primary completion date changed from estimate of Dec 31, 2024 to Jul 7, 2025
Results posted: Sep 22, 2026
Completed without a posted recruiting period
Final enrollment: 70 participants (planned 100)
Secondary endpoints: details revised at 1 of 1 entry
Publications: details revised at 1 of 1 entry
Eligibility criteria expanded, about 3 words
MinorRe-verified, no change to tracked fieldsv5
NotablePrimary and study completion dates changed from estimate of Dec 31, 2024 to Jul 7, 2025v4Show 5 more changesShow less
Primary endpoints revised (3)
Trial status: Not Yet Recruiting to Completed
Enrollment target: estimated 100 to confirmed 70
Start date changed from estimate of Sep 30, 2024 to Oct 1, 2024
Secondary endpoint revised
NotableStart date: May 1, 2024 to Sep 30, 2024v3
NotablePrimary endpoints revised (3)
Secondary endpoint revised
Eligibility criteria expanded, about 1 word
v2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
To raise the standard of care, improve the overall patient experience and streamline practice flow, Eyenovia has developed an innovative mydriatic to be delivered as a microdose by a specialized dispenser. While still achieving effective pupil dilation, MydCombi has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery. The proposed study hopes to demonstrate the non-inferiority of using MydCombi to achieve pupillary dilation in patients compared to standard of care eye drops.